Although no studies have reported a relation between β3-AR agonists and PS1 or BACE-1, the beneficial role of a β3-AR agonist against Aβ was reported in a model of AD, where it helped to avert the Aβ-induced memory loss, whereas the effect of a β2 agonist was more limited (Gibbs, 2015). Here, BACE1 is linked to Alzheimer disease.